Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis.

Pharmaceuticals (Basel) · 2023 · PMC10053019 · PMID 36986509

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The results demonstrated a highly significant direct impact of ETI therapy on self-report abdominal symptoms in PwCF and the mean total CFAbd-Score decreased by 29% over the study follow-up.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.